{"schema_version":"secwatch.filing_event.v1","accession":"0000875320-25-000029","form_type":"8-K","ticker":"VRTX","cik":"0000875320","company_name":"VERTEX PHARMACEUTICALS INC / MA","filed_at":"2025-02-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:06.577762+00:00","generated_at":"2026-05-27T00:41:13.541451+00:00","sec_items":["2.02","5.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Vertex 2024 product revenue $11.02B (+12% YoY); GAAP loss $536M from IPR&D; FY2025 guidance $11.75-12.0B","bullets":["Q4 product revenue $2.91B (+16% YoY); full-year product revenue $11.02B (+12%) driven by TRIKAFTA/KAFTRIO.","GAAP net loss $536M for 2024 due to $4.4B AIPR&D from Alpine Immune Sciences acquisition; non-GAAP net income $111M.","FY2025 total revenue guidance $11.75-12.0B; combined non-GAAP R&D, AIPR&D, SG&A expenses guided at $4.9-5.0B.","COO Stuart Arbuckle retiring July 1, 2025; CFO Charlie Wagner to add COO role, Duncan McKechnie to become CCO.","JOURNAVX approved Jan 30, 2025 for moderate-to-severe acute pain; ALYFTREK approved Dec 20, 2024 for CF ages 6+."],"urls":{"canonical":"https://secwatch.observer/filing/0000875320-25-000029","json":"https://secwatch.observer/filing/0000875320-25-000029.json","markdown":"https://secwatch.observer/filing/0000875320-25-000029.md","text":"https://secwatch.observer/filing/0000875320-25-000029.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/875320/000087532025000029/0000875320-25-000029-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/875320/000087532025000029/vrtx-20250204.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-27T00:41:13.541451+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"21dfb33006","claim":"Duncan J. McKechnie was appointed as Chief Commercial Officer at VERTEX PHARMACEUTICALS INC / MA.","evidence_excerpt":"the appointment of Duncan J. McKechnie as Chief Commercial Officer of the Company","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/875320/000087532025000029/0000875320-25-000029-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Commercial Officer"}]},{"claim_id":"ea17eab2d1","claim":"Charles F. Wagner, Jr. was appointed as Chief Operating Officer at VERTEX PHARMACEUTICALS INC / MA.","evidence_excerpt":"The Company also announced the appointment of Charles F. Wagner, Jr. as Chief Operating Officer of the Company","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/875320/000087532025000029/0000875320-25-000029-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Operating Officer"}]},{"claim_id":"f1f5477492","claim":"Stuart A. Arbuckle retired as Executive Vice President and Chief Operating Officer at VERTEX PHARMACEUTICALS INC / MA.","evidence_excerpt":"On February 10, 2025, Vertex Pharmaceuticals Incorporated (the “Company”) announced the retirement of Stuart A. Arbuckle, the Company’s Executive Vice President and Chief Operating Officer, effective on July 1, 2025.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/875320/000087532025000029/0000875320-25-000029-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"retired"},{"label":"Role","value":"Executive Vice President and Chief Operating Officer"}]}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}